Ikerian announces commercial expansion of RetinAI Discovery in Europe

News
Article

New investment from Sanoptis will support Ikerian technology for large-scale, AI-enabled data management

From left: Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; Sandro De Zanet, PhD, Chief Scientific Officer and co-founder, Ikerian AG and RetinAI US Inc. (Image credit: Ikerian AG)

From left: Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; Sandro De Zanet, PhD, Chief Scientific Officer and co-founder, Ikerian AG and RetinAI US Inc. (Image credit: Ikerian AG)

Ikerian AG, the Bern, Switzerland-based parent company of RetinAI, announced outcomes of first close Series B funding and a subsequent commercialisation agreement. New strategic investor Sanoptis, an ophthalmology services provider, led the €7.4 million ($8 million USD) funding round. Alongside the equity investment, Ikerian announced that Sanoptis will support the distribution of the RetinAI DISCOVERY platform within the existing Sanoptis network throughout Europe. DISCOVERY and its artificial intelligence (AI) models, supported by generative AI tools, will enhance clinical workflows, improve diagnostic pathways and efficiency and personalise treatment pathways for patients.1 According to a press release from Ikerian, the DISCOVERY platform was placed in a select group of Sanoptis clinics in early Q4 2024.

In Q1 2025, Ikerian and RetinAI will accelerate development of DISCOVERY CONNECT. The software solution allows clinicians to anonymise, automate and synchronise imaging data uploads. The secure health information platform aims to enable clinical decision-making and facilitate data collection without compromising patient privacy. DISCOVERY CONNECT will also support “real-world evidence generation and optimised clinical study recruitment processes,” Ikerian noted.1 The investment will also allow Ikerian to explore new oculomic avenues, including neurodegenerative disorders, vascular conditions and rare diseases.

Carlos Ciller, Chairman and CEO of Ikerian and CEO of RetinAI, said Ikerian and RetinAI hope to broaden the application of AI beyond ophthalmology, utilising the eye as a window to full-body health. “This funding allows us to enhance our platform and connectivity solutions further, ensuring clinics have uninterrupted, real-time access to critical information,” Dr Ciller said.1 “By improving data connectivity, we are helping healthcare providers in ophthalmology make more informed decisions and ultimately improve the quality of care for patients.”

Volker Wendel, CEO of Sanoptis, also commented on the new partnership. “Together, we will focus on advancing technologies that empower clinicians, enhance workflow efficiency and importantly, improve patient outcomes. This partnership marks a major step forward in transforming clinical practice for the better,” he said.

The Series B close was made possible through follow-on investment by existing investors: THINC Ventures, an arm of Topcon Healthcare, Inc.; Zürcher Kantonalbank and Verve Ventures.

Reference

1. Ikerian AG. Ikerian Announces Series B Funding First close of USD 8M (CHF 6.73M) Led by Sanoptis with Commercial Agreement to Expand RetinAI Discovery in Europe. Press release. Published 16 October, 2024. Accessed 25 October, 2024.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.